ERBB2 and neoplasm: With respect to pCR, it was already demonstrated that HER2-tumours are less likely to achieve pCR when treated with anti-HER2 therapies if they bear mutations in PIK3CA, which is a downstream member of the HER2 signalling cascade [56,57].